The word is that Pfizer has decided to exit neuroscience completely. I’m told there there are many layoffs involved, although the company itself does not seem to have made any announcement. That’s an important therapeutic area at a very big organization, so this is something to think about. The company seems to be making a strong statement about the likelihood of success in these projects, and it’s not a comforting one.
Similarly, I have from two sources that the Pfizer site in Andover (MA) is seeing big cuts in their Drug Safety and Metabolism department. More details on these as things become clearer (some may show up in the comments).